Tim Anderson
Stock Analyst at B of A Securities
(4.24)
# 411
Out of 4,859 analysts
34
Total ratings
75%
Success rate
9.54%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Tim Anderson
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| REGN Regeneron Pharmaceuticals | Maintains: Underperform | $575 → $547 | $521.84 | +4.82% | 2 | Apr 17, 2025 | |
| JNJ Johnson & Johnson | Maintains: Neutral | $171 → $159 | $156.66 | +1.49% | 5 | Apr 10, 2025 | |
| AARD Aardvark Therapeutics | Maintains: Buy | $22 → $26 | $11.00 | +136.36% | 2 | Mar 27, 2025 | |
| GILD Gilead Sciences | Maintains: Buy | $116 → $126 | $112.05 | +12.45% | 3 | Mar 5, 2025 | |
| AMGN Amgen | Maintains: Underperform | $275 → $294 | $297.29 | -1.11% | 4 | Mar 5, 2025 | |
| ABBV AbbVie | Maintains: Neutral | $200 → $223 | $192.42 | +15.89% | 5 | Mar 4, 2025 | |
| MTSR Metsera | Initiates: Buy | $38 | $34.58 | +9.89% | 1 | Feb 25, 2025 | |
| MRNA Moderna | Maintains: Underperform | $41 → $34 | $27.35 | +24.31% | 2 | Feb 11, 2025 | |
| MRK Merck & Co. | Maintains: Buy | $118 → $112 | $81.82 | +36.89% | 4 | Feb 5, 2025 | |
| PFE Pfizer | Reinstates: Neutral | $29 | $24.84 | +16.75% | 1 | Dec 10, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reinstates: Neutral | $63 | $50.69 | +24.28% | 1 | Dec 10, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reinstates: Neutral | $178 | $132.31 | +34.53% | 1 | Dec 10, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reinstates: Buy | $997 | $812.03 | +22.78% | 1 | Dec 10, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Peer Perform | n/a | $120.77 | - | 1 | May 9, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | n/a | $75.00 | - | 1 | Sep 22, 2017 |
Regeneron Pharmaceuticals
Apr 17, 2025
Maintains: Underperform
Price Target: $575 → $547
Current: $521.84
Upside: +4.82%
Johnson & Johnson
Apr 10, 2025
Maintains: Neutral
Price Target: $171 → $159
Current: $156.66
Upside: +1.49%
Aardvark Therapeutics
Mar 27, 2025
Maintains: Buy
Price Target: $22 → $26
Current: $11.00
Upside: +136.36%
Gilead Sciences
Mar 5, 2025
Maintains: Buy
Price Target: $116 → $126
Current: $112.05
Upside: +12.45%
Amgen
Mar 5, 2025
Maintains: Underperform
Price Target: $275 → $294
Current: $297.29
Upside: -1.11%
AbbVie
Mar 4, 2025
Maintains: Neutral
Price Target: $200 → $223
Current: $192.42
Upside: +15.89%
Metsera
Feb 25, 2025
Initiates: Buy
Price Target: $38
Current: $34.58
Upside: +9.89%
Moderna
Feb 11, 2025
Maintains: Underperform
Price Target: $41 → $34
Current: $27.35
Upside: +24.31%
Merck & Co.
Feb 5, 2025
Maintains: Buy
Price Target: $118 → $112
Current: $81.82
Upside: +36.89%
Pfizer
Dec 10, 2024
Reinstates: Neutral
Price Target: $29
Current: $24.84
Upside: +16.75%
Dec 10, 2024
Reinstates: Neutral
Price Target: $63
Current: $50.69
Upside: +24.28%
Dec 10, 2024
Reinstates: Neutral
Price Target: $178
Current: $132.31
Upside: +34.53%
Dec 10, 2024
Reinstates: Buy
Price Target: $997
Current: $812.03
Upside: +22.78%
May 9, 2022
Downgrades: Peer Perform
Price Target: n/a
Current: $120.77
Upside: -
Sep 22, 2017
Upgrades: Outperform
Price Target: n/a
Current: $75.00
Upside: -